Candriam S.C.A. Reduces Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Candriam S.C.A. lowered its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 10.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 212,416 shares of the biopharmaceutical company’s stock after selling 25,868 shares during the quarter. Candriam S.C.A. owned about 0.16% of Alnylam Pharmaceuticals worth $96,862,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in shares of Alnylam Pharmaceuticals by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company’s stock worth $4,336,064,000 after acquiring an additional 240,534 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Alnylam Pharmaceuticals by 3.3% during the second quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock valued at $779,857,000 after purchasing an additional 75,936 shares in the last quarter. Orbis Allan Gray Ltd grew its stake in Alnylam Pharmaceuticals by 29.8% in the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after purchasing an additional 486,489 shares during the period. Norges Bank bought a new position in Alnylam Pharmaceuticals in the second quarter worth $662,837,000. Finally, American Century Companies Inc. lifted its position in Alnylam Pharmaceuticals by 1.9% during the second quarter. American Century Companies Inc. now owns 1,793,846 shares of the biopharmaceutical company’s stock valued at $584,957,000 after buying an additional 33,411 shares during the period. 92.97% of the stock is owned by institutional investors.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,510 shares of the business’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.87, for a total transaction of $547,933.70. Following the completion of the sale, the executive vice president directly owned 29,728 shares in the company, valued at approximately $10,787,399.36. The trade was a 4.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Pushkal Garg sold 1,510 shares of the stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $547,933.70. Following the transaction, the executive vice president directly owned 22,511 shares in the company, valued at $8,168,566.57. The trade was a 6.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 56,955 shares of company stock valued at $24,072,733 over the last quarter. 1.20% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $328.16 on Monday. The company’s 50-day simple moving average is $389.54 and its two-hundred day simple moving average is $425.73. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54. The stock has a market capitalization of $43.35 billion, a P/E ratio of 1,367.33 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $495.55.

Wall Street Analyst Weigh In

Several research firms recently commented on ALNY. Truist Financial dropped their price objective on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. Stifel Nicolaus raised their price target on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a report on Thursday, December 11th. HC Wainwright dropped their price target on shares of Alnylam Pharmaceuticals from $570.00 to $510.00 and set a “buy” rating on the stock in a research note on Friday, January 30th. Barclays initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, January 28th. They set an “overweight” rating and a $527.00 price objective for the company. Finally, Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 10th. Twenty-two investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $477.13.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.